The Breast Cancer With No Target May Have One: NOS The Breast Cancer With No Target May Have One: NOS

For patients with chemo-resistant, locally advanced and metastatic triple-negative breast cancer, a first-in-class agent in combination with docetaxel yielded an overall response rate of almost 46%.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news